{"name":"GBG Forschungs GmbH","slug":"gbg-forschungs-gmbh","ticker":"","exchange":"","domain":"","description":"GBG Forschungs GmbH is a specialized pharmaceutical company with a robust pipeline of 35 drugs, primarily focused on oncology treatments. The company is dedicated to advancing cancer therapies through clinical research and development, with several drugs in late-stage trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Ibandronate, Capecitabine","genericName":"Ibandronate, Capecitabine","slug":"ibandronate-capecitabine","indication":"Metastatic breast cancer with bone involvement","status":"phase_3"},{"name":"Palbociclib PD-0332991","genericName":"Palbociclib PD-0332991","slug":"palbociclib-pd-0332991","indication":"Hormone receptor-positive, HER2-negative breast cancer","status":"phase_3"},{"name":"Tamoxifen and GnRH analogue","genericName":"Tamoxifen and GnRH analogue","slug":"tamoxifen-and-gnrh-analogue","indication":"Treatment of hormone receptor-positive metastatic breast cancer","status":"phase_3"},{"name":"Cyclophosphamide, Methotrexate, 5 FU","genericName":"Cyclophosphamide, Methotrexate, 5 FU","slug":"cyclophosphamide-methotrexate-5-fu","indication":"Breast cancer","status":"phase_2"},{"name":"Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa","genericName":"Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa","slug":"epirubicin-cyclophosphamide-paclitaxel-dabepoetin-alfa","indication":"Breast cancer (likely early-stage or metastatic, based on typical EC-T regimen use)","status":"phase_3"},{"name":"Exemestane and GnRH analogue","genericName":"Exemestane and GnRH analogue","slug":"exemestane-and-gnrh-analogue","indication":"Hormone receptor-positive breast cancer in premenopausal women (adjuvant or metastatic setting)","status":"phase_3"},{"name":"epirubicin - cyclophosphamide / docetaxel + bevacizumab","genericName":"epirubicin - cyclophosphamide / docetaxel + bevacizumab","slug":"epirubicin-cyclophosphamide-docetaxel-bevacizumab","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"epirubicin - cyclophosphamide / docetaxel + lapatinib","genericName":"epirubicin - cyclophosphamide / docetaxel + lapatinib","slug":"epirubicin-cyclophosphamide-docetaxel-lapatinib","indication":"Advanced or metastatic breast cancer","status":"phase_3"},{"name":"epirubicin - cyclophosphamide / docetaxel + trastuzumab","genericName":"epirubicin - cyclophosphamide / docetaxel + trastuzumab","slug":"epirubicin-cyclophosphamide-docetaxel-trastuzumab","indication":"Adjuvant treatment of node-positive breast cancer","status":"phase_3"},{"name":"non-pegylated liposomal doxorubicin","genericName":"non-pegylated liposomal doxorubicin","slug":"non-pegylated-liposomal-doxorubicin","indication":"Metastatic breast cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Ibandronat","genericName":"Ibandronat","slug":"ibandronat","indication":"Other","status":"marketed"},{"name":"NX","genericName":"NX","slug":"nx","indication":"Erosive esophagitis","status":"marketed"}]}],"pipeline":[{"name":"Ibandronat","genericName":"Ibandronat","slug":"ibandronat","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ibandronate, Capecitabine","genericName":"Ibandronate, Capecitabine","slug":"ibandronate-capecitabine","phase":"phase_3","mechanism":"This combination uses ibandronate to inhibit bone resorption and capecitabine to inhibit thymidylate synthase for antitumor activity.","indications":["Metastatic breast cancer with bone involvement"],"catalyst":""},{"name":"Palbociclib PD-0332991","genericName":"Palbociclib PD-0332991","slug":"palbociclib-pd-0332991","phase":"phase_3","mechanism":"Palbociclib is a CDK4/6 inhibitor that works by blocking the activity of cyclin-dependent kinases 4 and 6, which are involved in cell cycle progression.","indications":["Hormone receptor-positive, HER2-negative breast cancer"],"catalyst":""},{"name":"Tamoxifen and GnRH analogue","genericName":"Tamoxifen and GnRH analogue","slug":"tamoxifen-and-gnrh-analogue","phase":"phase_3","mechanism":"Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's proliferative effects on breast cancer cells, while GnRH analogue works by downregulating GnRH receptors in the pituitary gland, leading to decreased gonadotropin secretion and subsequently reduced estrogen production.","indications":["Treatment of hormone receptor-positive metastatic breast cancer","Treatment of hormone-sensitive breast cancer"],"catalyst":""},{"name":"Cyclophosphamide, Methotrexate, 5 FU","genericName":"Cyclophosphamide, Methotrexate, 5 FU","slug":"cyclophosphamide-methotrexate-5-fu","phase":"phase_2","mechanism":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and 5 FU is a thymidylate synthase inhibitor.","indications":["Breast cancer","Lymphoma"],"catalyst":""},{"name":"Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa","genericName":"Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa","slug":"epirubicin-cyclophosphamide-paclitaxel-dabepoetin-alfa","phase":"phase_3","mechanism":"This combination regimen uses chemotherapy agents (epirubicin, cyclophosphamide, paclitaxel) to damage cancer cell DNA and inhibit microtubule function, while dabepoetin alfa stimulates red blood cell production to counteract chemotherapy-induced anemia.","indications":["Breast cancer (likely early-stage or metastatic, based on typical EC-T regimen use)"],"catalyst":""},{"name":"Exemestane and GnRH analogue","genericName":"Exemestane and GnRH analogue","slug":"exemestane-and-gnrh-analogue","phase":"phase_3","mechanism":"Exemestane suppresses estrogen production while a GnRH analogue suppresses ovarian function, providing dual hormonal blockade in premenopausal women with hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive breast cancer in premenopausal women (adjuvant or metastatic setting)"],"catalyst":""},{"name":"NX","genericName":"NX","slug":"nx","phase":"marketed","mechanism":"Nexium works by reducing the amount of acid produced in the stomach.","indications":["Erosive esophagitis","Gastroesophageal reflux disease (GERD)","Zollinger-Ellison syndrome"],"catalyst":""},{"name":"epirubicin - cyclophosphamide / docetaxel + bevacizumab","genericName":"epirubicin - cyclophosphamide / docetaxel + bevacizumab","slug":"epirubicin-cyclophosphamide-docetaxel-bevacizumab","phase":"phase_3","mechanism":"Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis.","indications":["Metastatic breast cancer","Locally advanced or metastatic breast cancer"],"catalyst":""},{"name":"epirubicin - cyclophosphamide / docetaxel + lapatinib","genericName":"epirubicin - cyclophosphamide / docetaxel + lapatinib","slug":"epirubicin-cyclophosphamide-docetaxel-lapatinib","phase":"phase_3","mechanism":"Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 and EGFR receptors.","indications":["Advanced or metastatic breast cancer","Adjuvant treatment of node-positive breast cancer"],"catalyst":""},{"name":"epirubicin - cyclophosphamide / docetaxel + trastuzumab","genericName":"epirubicin - cyclophosphamide / docetaxel + trastuzumab","slug":"epirubicin-cyclophosphamide-docetaxel-trastuzumab","phase":"phase_3","mechanism":"Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II, while cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division, and trastuzumab is a monoclonal antibody that targets the HER2/neu receptor.","indications":["Adjuvant treatment of node-positive breast cancer","Metastatic breast cancer with overexpression of HER2/neu"],"catalyst":""},{"name":"non-pegylated liposomal doxorubicin","genericName":"non-pegylated liposomal doxorubicin","slug":"non-pegylated-liposomal-doxorubicin","phase":"phase_3","mechanism":"Non-pegylated liposomal doxorubicin is a chemotherapy medication that works by intercalating DNA strands, thereby inhibiting the progression of the enzyme topoisomerase II and inducing apoptosis in cancer cells.","indications":["Metastatic breast cancer","Ovarian cancer","Multiple myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9zd2UtZGFyTTdqd1JaUXJudUktU21HSHhjdS1GY3ZoQXA3VTdmQ3JwdVFNREU5SmtUSXkwRGhleElMM0JCYkhISG5YWTJaeTlRblVZOFM1ZUFhWkt2c3Vn?oc=5","date":"2025-05-14","type":"pipeline","source":"Nature","summary":"Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification | npj Breast Cancer - Nature","headline":"Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification | npj Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUmR6VmxCclp1MFJVY1JmcE1SNzlVRkRseVlHZTM0NzFFMmFieEdWX1F2RGJKX3U1c1ZmSG9GdHlFSzg3ZTR4ZzZqb1l0bjlueXJMbmFhbDZMT2JLblRVY0hXa3o0TExrUVlGV3VqSTZ4WW15R3ljOEZnWVlqSWlxY051dGdWX25ndmRKdDBNR0ZXWHhRejRHMjdUZTRxemo1cGl4bUxIR0Yyb0Y2a3NTZEdKU2I5NFJiR2pKY2lSVFNRUQ?oc=5","date":"2024-12-11","type":"pipeline","source":"Oncology News Central","summary":"Palbociclib Plus Endocrine Therapy Beats Chemo in HR+/HER2− Metastatic Breast Cancer - Oncology News Central","headline":"Palbociclib Plus Endocrine Therapy Beats Chemo in HR+/HER2− Metastatic Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOZ2Y0RjRMNUxTV2ZYc2lNSTN6MG5LQnNtRVBWT3BfQ1lRNDFZVHdGQ2VpTXUzaVpxelpMVmZvVkk5OEkyYmVvMzNSRmhQRE01R2xSVzJtZ1lTOW5oS3luMWFtbkNuSHA1aUxQemJpdklwc3VQVnVHNVlTS2d6VS1LY216UkY2ZUFUaDdXRVBocjV5SDMyQ2hBRkh0SThQRXlIdkstakl1b1YwQnJUaU1waWRBcHNPblZyYWRNMVF5SVZfM1JjMFZCbWlhTldadVliclJnNDhucVlpX1g1UmZXelFGRnhoMHNIYVl3?oc=5","date":"2021-02-01","type":"trial","source":"MedUni Wien","summary":"BIGPICTURE: European alliance uses AI with a database of pathology images - MedUni Wien","headline":"BIGPICTURE: European alliance uses AI with a database of pathology images","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"marketed":2,"phase_3":9,"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}